{"id":59136,"date":"2024-02-28T05:43:26","date_gmt":"2024-02-28T05:43:26","guid":{"rendered":"https:\/\/medsname.com\/risdone\/"},"modified":"2026-04-30T10:24:03","modified_gmt":"2026-04-30T10:24:03","slug":"risdone","status":"publish","type":"product","link":"https:\/\/medsbase.com\/nb\/product\/risdone\/","title":{"rendered":"Risdone"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 Raskt svar<\/h3>\n

Risdone (Risperidone 1 \/ 2 \/ 3 \/ 4 mg) is an atypical antipsychotic for schizophrenia, bipolar mania, irritability in autism (paediatric and adolescent), and short-term aggression in dementia. Highest prolactin elevation of any atypical \u2014 relevant for fertility, menstrual function, and bone density.<\/p>\n<\/div>\n

\nHva du f\u00e5r med MedsBase:<\/strong> WHO-GMP-sertifisert produsent \u00b7 Diskret emballasje \u00b7 Verdensomspennende levering \u00b7 1 400+ verifiserte kundeanmeldelser<\/a>\n<\/div>\n

\ud83d\udce6 Hver ordre er dekket av v\u00e5r Reshipment Assurance Policy<\/strong><\/a> \u2014 hvis pakken din ikke ankommer innen 20 virkedager, sender vi ny.<\/p>\n

Hvorfor bestille fra MedsBase<\/h3>\n

Risdone at MedsBase is supplied directly from a WHO-GMP certified manufacturer in plain, discreet packaging. Every order is covered by our Reshipment Assurance Policy<\/a> \u2014 20 virkedagers leveringsvindu eller vi sender p\u00e5 nytt uten ekstra kostnad \u2014 og kvalifiserer for v\u00e5rt kundelojalitetsprogram<\/a>. Verdensomspennende shipping er tilgjengelig til de fleste destinasjoner.<\/p>\n

What Risdone is and how it works<\/h2>\n

Risdone is a risperidone tablet supplied by Sun Pharma. Available strengths: 1 \/ 2 \/ 3 \/ 4 mg<\/strong>. Risperidone is a strong D2 and 5-HT2A antagonist with \u03b11-adrenergic and H1 antihistamine activity, but minimal anticholinergic effect. The strong D2 blockade explains both the strong antipsychotic effect and the high rate of EPS and prolactin elevation.<\/p>\n

Indikasjoner og dosering<\/h2>\n\n\n\n\n\n\n\n\n\n
Indikasjon<\/th>\nStartdose<\/th>\nM\u00e5ldose<\/th>\nMaks<\/th>\n<\/tr>\n<\/thead>\n
Schizofreni (voksen)<\/td>\n1\u20132 mg OD or BID<\/td>\n4\u20136 mg\/day<\/td>\n16 mg<\/td>\n<\/tr>\n
Schizofreni (ungdom \u2265 13 \u00e5r)<\/td>\n0.5 mg OD<\/td>\n3 mg\/day<\/td>\n6 mg<\/td>\n<\/tr>\n
Bipolar mania<\/td>\n2\u20133 mg OD<\/td>\n2\u20136 mg\/day<\/td>\n6 mg<\/td>\n<\/tr>\n
Autism irritability (paediatric \u2265 5 y)<\/td>\n0.25\u20130.5 mg OD<\/td>\n0.5\u20133 mg\/day weight-based<\/td>\n2.5\u20133 mg<\/td>\n<\/tr>\n
Eldre\/demens (off-label, siste utvei)<\/td>\n0.25 mg OD<\/td>\n0.5\u20131 mg\/day<\/td>\n2 mg<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Viktige sikkerhetshensyn<\/h2>\n
\nFDA black-box \u2014 demensrelatert psykose<\/strong><\/p>\n

Alle atypiske antipsykotika b\u00e6rer en FDA black-box advarsel for \u00f8kt d\u00f8delighet (hovedsakelig kardiovaskul\u00e6r og infeksi\u00f8s) n\u00e5r de brukes til \u00e5 behandle atferdsforstyrrelser hos eldre med demens. Atypiske antipsykotika er ikke godkjent for demensrelatert psykose eller agitasjon<\/strong>. Bruk i denne populasjonen er off-label, siste utvei, tidsbegrenset, og krever eksplisitt risikovurderingssamtale.<\/p>\n<\/div>\n

\nHighest prolactin elevation of any atypical<\/strong><\/p>\n

Risperidone produces marked, dose-dependent hyperprolactinaemia. Clinical consequences:<\/strong> amenorrhoea, galactorrhoea, anovulation, and reduced bone density in women; loss of libido, erectile dysfunction, and gynaecomastia in men; in long-term use, accelerated osteoporosis. Check prolactin if symptoms suggest hyperprolactinaemia. If hyperprolactinaemia is symptomatic, consider switching to aripiprazole (lowers prolactin) or quetiapine.<\/p>\n<\/div>\n

\nEPS \/ dose-dependent<\/strong><\/p>\n

Above approximately 6 mg\/day, risperidone increasingly behaves like a typical antipsychotic on EPS \u2014 rigidity, tremor, akathisia, dystonia. Tardive dyskinesia risk is real but lower than typicals. Stay below 6 mg\/day where possible.<\/p>\n<\/div>\n

\nOrthostatisk hypotensjon<\/strong><\/p>\n

\u03b11 antagonism \u2014 common at initiation, particularly in older adults. Titrate slowly.<\/p>\n<\/div>\n

\nMetabolic burden<\/strong><\/p>\n

Less than olanzapine but real \u2014 weight gain typically 2\u20134 kg over 6 months. Monitor weight, fasting glucose, fasting lipids at baseline, 12 weeks, then 6-monthly.<\/p>\n<\/div>\n

Vanlige bivirkninger<\/h2>\n